Investment Thesis

.

Competitive Moat

anchored in its strong portfolio of patented drugs and advanced R&D capabilities, making it a leader in the neurological treatment sector. The company's intangible assets, including a reputation for innovation and established brand loyalty, create high switching costs for healthcare providers and patients. Over the next 5-10 years, this moat is expected to remain durable, although competition from emerging biosimilars and novel therapies from companies like Eli Lilly and Amgen poses a significant threat to market share.

Growth Engine

Future revenue growth for Biogen will largely stem from its expanding portfolio of neurodegenerative disease therapies, particularly ADUHELM and Lecanemab for Alzheimer’s, which address a significant total addressable market (TAM) that is projected to grow as global demographics shift toward an aging population. The company is also poised to capture additional market share through new product launches and geographic expansion, particularly in international markets where neurological disorders are on the rise. Biogen's focus on organic growth through innovation, rather than aggressive acquisitions, positions it well to capture this growth sustainably.